Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Acquisitions & Divestments: 2016-2025

Historic Change in Acquisitions & Divestments for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $135.6 million.

  • Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments rose 44.90% to $135.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $481.2 million, marking a year-over-year increase of 19.13%. This contributed to the annual value of $410.0 million for FY2024, which is 41.05% down from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments stood at $135.6 million, which was up 51.67% from $89.4 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments ranged from a high of $224.2 million in Q1 2021 and a low of $42.8 million during Q4 2022.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Change in Acquisitions & Divestments value was $128.8 million (recorded in 2024), while the average stood at $133.4 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments surged by 164.83% in 2023 and then plummeted by 68.32% in 2024.
  • Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments (Quarterly) stood at $134.1 million in 2021, then crashed by 68.10% to $42.8 million in 2022, then spiked by 164.83% to $113.3 million in 2023, then increased by 5.34% to $119.3 million in 2024, then soared by 44.90% to $135.6 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $135.6 million for Q3 2025, versus $89.4 million for Q2 2025 and $136.9 million for Q1 2025.